{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:57:13Z","timestamp":1790326633243,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-023-03534-0","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T18:02:11Z","timestamp":1695319331000},"page":"392-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting"],"prefix":"10.1007","volume":"83","author":[{"given":"Khaled","family":"Alabduljabbar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moath","family":"Alsaqaaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl J.","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Crotty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel W.","family":"le Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"3534_CR1","unstructured":"A.Y. Yeung and P. Tadi, \u201cPhysiology, Obesity Neurohormonal Appetite And Satiety Control,\u201d in StatPearls. Treasure Island (FL): StatPearls Publishing, 2022."},{"key":"3534_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.metabol.2018.09.005","volume":"92","author":"YC Chooi","year":"2019","unstructured":"Y.C. Chooi, C. Ding, F. Magkos, The epidemiology of obesity. Metabolism 92, 6\u201310 (2019). https:\/\/doi.org\/10.1016\/j.metabol.2018.09.005","journal-title":"Metabolism"},{"issue":"5","key":"3534_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","volume":"15","author":"M Bl\u00fcher","year":"2019","unstructured":"M. Bl\u00fcher, Obesity: global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 15(5), 288\u2013298 (2019). https:\/\/doi.org\/10.1038\/s41574-019-0176-8","journal-title":"Nat. Rev. Endocrinol."},{"key":"3534_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-88","volume":"9","author":"DP Guh","year":"2009","unstructured":"D.P. Guh, W. Zhang, N. Bansback, Z. Amarsi, C.L. Birmingham, A.H. Anis, The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 9, 88 (2009). https:\/\/doi.org\/10.1186\/1471-2458-9-88. (in eng)","journal-title":"BMC Public Health"},{"issue":"1","key":"3534_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53578-4","volume":"9","author":"K Thomas","year":"2019","unstructured":"K. Thomas et al. Higher body mass index is linked to altered hypothalamic microstructure. Sci. Rep. 9(1), 17373 (2019). https:\/\/doi.org\/10.1038\/s41598-019-53578-4","journal-title":"Sci. Rep."},{"key":"3534_CR6","doi-asserted-by":"publisher","unstructured":"S. Gabery et al. Semaglutide lowers body weight in rodents via distributed neural pathways. (in eng), JCI Insight, 5(6) (2020). https:\/\/doi.org\/10.1172\/jci.insight.133429.","DOI":"10.1172\/jci.insight.133429"},{"issue":"31","key":"3534_CR7","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.1503\/cmaj.191707","volume":"192","author":"S Wharton","year":"2020","unstructured":"S. Wharton et al. Obesity in adults: a clinical practice guideline. CMAJ 192(31), E875\u2013e891 (2020). https:\/\/doi.org\/10.1503\/cmaj.191707. (in eng)","journal-title":"CMAJ"},{"issue":"4","key":"3534_CR8","first-page":"395","volume":"109","author":"A Melvin","year":"2016","unstructured":"A. Melvin, C.W. Le Roux, N.G. Docherty, Which organ is responsible for the pathogenesis of obesity? Ir. Med. J. 109(4), 395 (2016). (in eng)","journal-title":"Ir. Med. J."},{"key":"3534_CR9","doi-asserted-by":"publisher","unstructured":"K. Alabduljabbar, W. Al-Najim, C.W. le Roux The impact once-weekly semaglutide 2.4 mg will have on clinical practice: A focus on the STEP trials. (in eng), Nutrients, 14(11) (2022). https:\/\/doi.org\/10.3390\/nu14112217.","DOI":"10.3390\/nu14112217"},{"issue":"19","key":"3534_CR10","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2146\/ajhp150990","volume":"73","author":"D Isaacs","year":"2016","unstructured":"D. Isaacs, L. Prasad-Reddy, S.B. Srivastava, Role of glucagon-like peptide 1 receptor agonists in management of obesity. Am. J. Health Syst. Pharm. 73(19), 1493\u20131507 (2016). https:\/\/doi.org\/10.2146\/ajhp150990. (in eng)","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"10321","key":"3534_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/s0140-6736(21)01640-8","volume":"399","author":"Q Shi","year":"2022","unstructured":"Q. Shi et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 399(10321), 259\u2013269 (2022). https:\/\/doi.org\/10.1016\/s0140-6736(21)01640-8. (in eng)","journal-title":"Lancet"},{"issue":"11","key":"3534_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"J.P.H. Wilding et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384(11), 989\u20131002 (2021). https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"3534_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"D.M. Rubino et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA 327(2), 138\u2013150 (2022). https:\/\/doi.org\/10.1001\/jama.2021.23619. (in eng)","journal-title":"JAMA"},{"issue":"10278","key":"3534_CR14","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/s0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"M. Davies et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278), 971\u2013984 (2021). https:\/\/doi.org\/10.1016\/s0140-6736(21)00213-0. (in eng)","journal-title":"Lancet"},{"issue":"14","key":"3534_CR15","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"T.A. Wadden et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA 325(14), 1403\u20131413 (2021). https:\/\/doi.org\/10.1001\/jama.2021.1831","journal-title":"JAMA"},{"issue":"14","key":"3534_CR16","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"D. Rubino et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA 325(14), 1414\u20131425 (2021). https:\/\/doi.org\/10.1001\/jama.2021.3224. (in eng)","journal-title":"JAMA"},{"issue":"10","key":"3534_CR17","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"W.T. Garvey et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat. Med. 28(10), 2083\u20132091 (2022). https:\/\/doi.org\/10.1038\/s41591-022-02026-4. (in eng)","journal-title":"Nat. Med"},{"issue":"3","key":"3534_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/s2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"T. Kadowaki et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol 10(3), 193\u2013206 (2022). https:\/\/doi.org\/10.1016\/s2213-8587(22)00008-0. (in eng)","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"3534_CR19","doi-asserted-by":"publisher","first-page":"161","DOI":"10.21037\/atm.2017.03.107","volume":"5","author":"M Abdelaal","year":"2017","unstructured":"M. Abdelaal, C.W. le Roux, N.G. Docherty, Morbidity and mortality associated with obesity. Ann. Transl. Med. 5(7), 161 (2017). https:\/\/doi.org\/10.21037\/atm.2017.03.107. (in eng)","journal-title":"Ann. Transl. Med"},{"issue":"2-3","key":"3534_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1758-8111.2011.00017.x","volume":"1","author":"ET Aasheim","year":"2011","unstructured":"E.T. Aasheim et al. Assessment of obesity beyond body mass index to determine benefit of treatment. Clin. Obes. 1(2-3), 77\u201384 (2011). https:\/\/doi.org\/10.1111\/j.1758-8111.2011.00017.x. (in eng)","journal-title":"Clin. Obes."},{"issue":"6","key":"3534_CR21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/oby.22462","volume":"27","author":"S Wharton","year":"2019","unstructured":"S. Wharton et al. Real-world clinical effectiveness of liraglutide 3.0 mg for weight management in Canada. Obesity (Silver Spring) 27(6), 917\u2013924 (2019). https:\/\/doi.org\/10.1002\/oby.22462. (in eng)","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"3534_CR22","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/oby.22794","volume":"28","author":"RF Kushner","year":"2020","unstructured":"R.F. Kushner et al. Semaglutide 2.4 mg for the treatment of obesity: Key elements of the STEP trials 1 to 5. Obesity (Silver Spring) 28(6), 1050\u20131061 (2020). https:\/\/doi.org\/10.1002\/oby.22794. (in eng)","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"3534_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","volume":"45","author":"VR Aroda","year":"2019","unstructured":"V.R. Aroda et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab 45(5), 409\u2013418 (2019). https:\/\/doi.org\/10.1016\/j.diabet.2018.12.001. (in eng)","journal-title":"Diabetes Metab"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03534-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03534-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03534-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T08:19:28Z","timestamp":1707293968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03534-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["3534"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03534-0","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"C.W. le Roux reports grants from the Irish Research Council, Science Foundation Ireland, Anabio, and the Health Research Board. He serves on advisory boards of Novo Nordisk, Herbalife, GI Dynamics, Eli Lilly, Johnson & Johnson, Sanofi Aventis, AstraZeneca, Janssen, Bristol-Myers Squibb, Glia, and Boehringer Ingelheim. He is a member of the Irish Society for Nutrition and Metabolism outside the area of work commented on here. He is the chief medical officer and director of the Medical Device Division of Keyron since January 2011. Both of these are unremunerated positions. C.W. le Roux was a previous investor in Keyron, which develops endoscopically implantable medical devices intended to mimic the surgical procedures of sleeve gastrectomy and gastric bypass. He continues to provide scientific advice to Keyron for no remuneration. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research complies with the guidelines for human studies and was conducted ethically in accordance with the World Medical Association the Declaration of Helsinki. The study was approved by the Research Ethics Committee at St Vincent\u2019s University Hospital (RCR22-031). Patient consent was waived due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}